The sale I referred to above was in my ISA. I'm determined to take advantage of trader antics and trade SBTX:SkinBioTherapeutics, as I regard it as a bonus holding due to my big stake via OPTI:Optibiotix. I sold my 9,260 shares for 23.2p after buying at 20p. This gave me a modest £272.42 (14.5%) profit. My plan was to hold the cash until SBTX:SkinBioTherapeutics dips under 20p and then buy back more than I had before. If this never happens, then no worries as I have my OPTI:Optibiotix allocation.
However, my discipline is hopeless and when I saw IQE:IQE being hammered due to the Trump administration deciding they don't like the competition from Huawei and trying to destroy them along with all the American companies that supply them, then I couldn't resist buying IQE:IQE with the proceeds with the intention of selling them in order buy back into SBTX:SkinBioTherapeutics. Knowing my trading track record, it ain't going to work. I bought 2,861 shares at 75.0795p costing £2,159.97. Needless to say my timing sucked and they dropped further today resulting in an 8% loss in one day when you include commission.
Worst performer by miles was IKA:Ilika, dropping 13%. There's absolutely no reason for the drop. No news. No nothing. It's an annoying mystery.
Next worst performer was IQE:IQE which now features in all three portfolios. In my trading account it dropped 12% of the 101.99p I bought them for. In my SIPP it dropped 10% of the 131.45p I bought them for, and my new holding in the ISA dropped 8% of the 75.0795p I paid when you add in the commission charges too, which I account for up-front.
Final big loser was JLP:Jubilee Metals which is one of my bigger holdings and fell 7%, probably due to profit taking following the recent rise.
OPTI:Optibiotix climbed 1p this week, which is only 2%, but that offset most of the losses elsewhere.
TLOU:Tlou Energy climbed 6% after it appears they have been accepted for tender by the Botswana Government, although it's still not really clear whether we have or not, which is why the rise is more muted than I'd hoped.
Very few big risers this week, so Share of the Week goes to MMX:Minds + Machines which climbed 9% after a good trading update on the .luxe domain and some really hefty director buys. It's taken much longer than I thought, but I still believe these will come good this year.
Torture - so close to getting back above the line, but not today.
Above the trend line so let's start dragging if flat again
Here's the ISA and share portfolio performance
| Weekly Change | |||
| Cash | £27.79 | -£23.60 | |
| Portfolio cost | £57,570.81 | +£296.03 | |
| Portfolio sell value (bid price - commission) | £55,734.07 | (-3.2%) | -£118.47 |
| Potential profits | £8,564.55 | +£401.95 | |
| Yr 4 Dividends | £88.07 | +£0 | |
| Yr 4 Profit from sales | £1,350.02 | +£272.42 | |
| Yr 4 Average monthly cash profit | £144.89 | (3%) | +£25.26 |
| Total Dividends | £1,326.40 | +£0 | |
| Total Profit from sales | £20,047.14 | +£272.42 | |
| Average monthly cash profit | £463.82 | (9.7%) | +£3.63 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash reduced as I added spare to the IQE:IQE purchase, which also explains the increase in cost. Potential profits rose by £401 largely thanks to OPTI:Optibiotix but the losses elsewhere mean there's a £118 deficit for the week. The SBTX:SkinBioTherapeutics sale boosted realised profits by £272 which only boosted average monthly performance by 0.1%. Only 0.3% below target 10% so not bad, especially given the increase in cost of the portfolio.
Still a way to go before getting back into the black.
Still above the trend line - yippee!
The SIPP looks like this after week 182
| Weekly Change | |||
| Cash | £421.50 | +£293.76 | |
| Portfolio cost | £40,725.38 | +£0 | |
| Portfolio sell value (bid price - commission) | £41,784.42 | (2.6%) | -£96.06 |
| Potential profits | £5,683.12 | +£183.76 | |
| Yr 4 Dividends | £361.99 | +£293.76 | |
| Yr 4 Interest | £0.07 | +£0 | |
| Yr 4 Profit from sales | £732.65 | +£0 | |
| Yr 4 Average monthly cash profit | £169.87 | (5%) | +£44.12 |
| Total Dividends | £1,704.24 | +£293.76 | |
| Total Interest | £0.10 | +£0 | |
| Total Profit from sales | £11,277.57 | +£0 | |
| Average monthly cash profit | £300.58 | (8.9%) | +£5.37 |
| (Sold stocks profit + Dividends - Fees / Months) |
A magnificent £293 dividend from CAML:Central Asia Metals resulted in improvements in monthly performance, albeit only 0.2% in the long term monthly profits. Deepening losses meant the £183 improvement in paper profits was wiped out into a £96 reduction in value.
Slight increase in the green line thanks to the dividend as it includes cash.
So close to getting above the trend line, but still on the wrong side and the peak is about to come into play big-time.
The trading portfolio looks like this after week 148
| Weekly Change | |||
| Cash | £35.04 | +£16.24 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,523.65 | (-34.4%) | -£58.92 |
| Potential profits | £0 | +£0 | |
| Year 3 Dividends | £33.57 | +£16.24 | |
| Year 3 Profit | £177.06 | +£0 | |
| Yr 3 Average monthly cash profit | £20.74 | (10.7%) | +£1.15 |
| Dividends | £34.72 | +£16.24 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£0.87 | (-0.4%) | +£0.48 |
| (Sold stocks profit + Dividends - Fees / Months) |
Bad week with multiple losses dragging things down by £58. Great news is the £16 dividend from CAML:Central Asia Metals which has improved performance a bit. We really shouldn't be getting dividends from a trading account though!
Still utterly hopeless
Still above the trend line so still dragging it flatter but there's a long way to go.
That's all the dividends out of the way. I'm desperately hoping for a quick improvement for IQE:IQE so I can get the cash back for when (or if) SBTX:SkinBioTherapeutics drops back below 20p. I'm determined to make amends for getting ripped off by not being able to join the IPO and paying 13p a share at 20 seconds past 8am when the IPO price was 9p. That's the problem when OPTI:Optibiotix sells off divisions and there's no way existing shareholders can be a part of it. We may get a big dividend in the future, but what we really want is to keep ownership of all the parts of our company.
No comments:
Post a Comment